On-Demand Webinars

  1. FDA Guidance: Inspection Of Injectable Products For Visible Particulate

    A review of the draft guidance and importance of component selection as it relates to establishing a risk-based approach and the role of the NovaPure product line in component selection.

  2. Practical Applications For Controlled And Safe Nucleic Acid Delivery 7/21/2025

    Explore the science behind LNP formulation development, from ionizable lipids to scalable manufacturing through case studies, screening strategies, and flexible approaches for advancing next-generation therapeutics.

  3. Advanced Nasal Drug Delivery: From Development To Commercialization 7/23/2026

    As nasal therapies advance, integrating formulation, device, manufacturing, and regulatory planning early helps reduce risk, accelerate launch, and support patient outcomes.

  4. The Best CDMO Fit For Small Molecule, Sterile Injectable Fill/Finish 7/19/2023

    "One stop” sterile injectable fill/finish capabilities can accelerate timelines and reduce costs. Explore August Bio’s operational flexibility and available capacity to support small-, mid-size, and large-scale batches.

  5. Nanoscale Technology's Potential: A Fireside Chat With Industry Leaders

    Nanoform CEO Edward Haeggstrom and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca, discuss the potential of nanoscale medicines and delivery devices.

  6. Navigating Regulatory Expectations For Injectable Packaging 12/4/2025

    Explore insights on extractables, focusing on how they relate to the revised EU GMP Annex 1, new and evolved expectations under USP <382>, and the use of VHP decontamination in aseptic environments.

  7. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing

    Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.

  8. Rapid Development Of Amorphous Solid Dispersions For Bioavailability

    See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

  9. Selecting Container Closure Systems With Confidence: Lyophilization 3/7/2024

    Experts take you through the entire selection process for primary packaging components for lyophilization and provide aspects to consider for all relevant attributes.

  10. Addressing Key Challenges Of High Concentration Formulation Development

    High concentration formulations often present challenges with regard to viscosity as well as potential changes in the behavior upon stability. Discover solutions to mitigate high viscosity.